Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rhizen Begins FIH Trial | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Rhizen Begins FIH Trial

Lead to target blood diseases

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Rhizen Pharmaceuticals has begun a first-in-human Phase I study of RP6530, a dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, for the treatment of patients with advanced hematological malignancies. The study is designed primarily to establish the safety and tolerability of RP6530. Secondary objectives include clinical efficacy assessment and biomarker response to allow dose determination and potential patient stratification in subsequent expansion studies. The study will be conducted at San Raffael Institute, Milan, Italy with Dr. Andres Ferrari as the Principal Investigator.

RP6530 is the second lead from Rhizen’s robust pipeline that comprises of small molecules targeting cancer, immuno-inflammation, and metabolic diseases, to enter clinical development. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of the tumor microenvironment at clinically achievable concentrations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics